Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-29 @ 11:14 AM
Study NCT ID:
NCT06060704
Status:
UNKNOWN
Last Update Posted:
2023-10-11
First Post:
2023-09-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
KEEP-G 09
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None